News

Massive Bio and Optellum have announced a strategic collaboration designed to connect early lung cancer detection with faster access to clinical trials, potentially addressing one of…
Read More...

Roche has moved a step closer to bringing a potential new treatment option to patients with early-stage breast cancer after the U.S. Food and Drug Administration (FDA) accepted the…
Read More...

AbbVie has secured a significant regulatory milestone in Europe after the European Commission approved AQUIPTA® (atogepant) for the acute treatment of migraine in adults, providing…
Read More...

Contraline, a clinical-stage biopharmaceutical company focused on developing innovative male contraceptives, has secured $92.5 million in Series B financing to advance the late-stage…
Read More...

CytomX Therapeutics has expanded its collaboration and licensing agreement with Regeneron Pharmaceuticals to advance the development of next-generation bispecific cancer therapies,…
Read More...

Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an…
Read More...

SystImmune and Bristol Myers Squibb have reported positive Phase 3 results for izalontamab brengitecan (iza-bren), an investigational bispecific antibody-drug conjugate (ADC),…
Read More...

Vertex Pharmaceuticals has moved a step closer to bringing a new treatment option to patients with immunoglobulin A nephropathy (IgAN) after the U.S. Food and Drug Administration (FDA)…
Read More...

Agios Pharmaceuticals has strengthened its position in rare hematology by securing exclusive global rights to cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK)…
Read More...

Servier has announced a major expansion of its neurology and rare disease portfolio through an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics in a deal…
Read More...

Bristol Myers Squibb has moved closer to expanding the use of its heart disease therapy Camzyos® (mavacamten) after the U.S. Food and Drug Administration (FDA) accepted a supplemental…
Read More...

Bristol Myers Squibb has received approval from the European Commission for Opdivo® (nivolumab) in combination with the chemotherapy regimen AVD (doxorubicin, vinblastine and…
Read More...

Ionis Pharmaceuticals and its partner GSK have reported positive Phase 3 results for bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B (CHB),…
Read More...

Sanofi has received a significant regulatory boost after the U.S. Food and Drug Administration (FDA) granted priority review to the new drug application (NDA) for venglustat, an…
Read More...

Innovent Biologics and Pfizer have entered into a major global oncology collaboration aimed at accelerating the development of next-generation cancer therapies, with a deal potentially…
Read More...

British pharmaceutical company GSK has reported encouraging late-stage clinical trial results for bepirovirsen, an investigational therapy for chronic hepatitis B (CHB), raising hopes…
Read More...

Novo Nordisk presented new findings from its landmark POSEIDON real-world evidence study showing that cardiovascular inflammation remains highly prevalent among people living with…
Read More...

SK bioscience has signed an agreement with Colombia’s state-owned pharmaceutical company VECOL to support vaccine technology transfer and local manufacturing, marking a significant step…
Read More...

Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. have entered into an exclusive licensing and collaboration agreement to develop and commercialize INBRIJA® (levodopa…
Read More...

Insilico Medicine and Human Life Foundation Models, Inc. (HLFM) have entered into a multi-million-dollar collaboration to develop what the companies describe as the biotechnology…
Read More...